Role of surgery in locally advanced prostate cancer

Pakistan Journal of Medical Sciences

Volumn 31, Issue 3, 2015, Pages 710-716

  Nazim, Syed Muhammad ^a   Abbas, Farhat ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Locally advanced; Prostate cancer; Radical prostatectomy; Surgery

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; JJ STENTING; MEDICAL PROCEDURES; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PERCUTANEOUS NEPHROSTOMY; PROSTATE CANCER; PROSTATE SURGERY; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SALVAGE THERAPY; SURGICAL TECHNIQUE; SYMPTOM; SYSTEMIC DISEASE; TRANSURETHRAL RESECTION;

EID: 84929591414     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.313.7103     Document Type: Review

References (40)

1. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate. 1983;4(5):473-485.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079- 1092. doi: 10.1016/j.eururo.2012.02.054.
3. Cullen J, Elsamanoudi S, Brassell SA, Chen Y, Colombo M, Srivastava A, et al. The burden of prostate cancer in Asian nations. J Carcinog. 2012;11:7. doi: 10.4103/1477-3163.94025.
4. Arshad H, Ahmad Z. Overview of benign and malignant prostatic disease in Pakistani patients: A clinical and histopathological perspective. Asian Pac J Cancer Prev. 2013;14(5):3005-3010.
5. Gnanapragasam VJ, Mason MD, Shaw GL, Neal DE. The role of surgery in high-risk localised prostate cancer. BJU Int. 2012;109(5):648-658. doi: 10.1111/j.1464-410X.2011.10596.x.
6. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974.
7. Van Poppel H, Vekemans K, Da Pozzo L, Bono A, Kliment J, Montironi R, et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer. 2006;42(8):1062-1067.
8. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Longterm outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol. 2006;176(2):564-568.
9. Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC. Radical prostatectomy for clinical stage T3a disease. Cancer. 2007;109:1273–1278.
10. Hsu CY, Wildhagen MF, Van Poppel H, Bangma CH. Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy. BJU Int. 2010;105(11):1536-1540. doi: 10.1111/j.1464-410X.2009.09054.x.
11. Xylinas E, Drouin SJ, Comperat E, Vaessen C, Renard- Penna R, Misrai V, et al. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: A single-centre experience. BJU Int. 2009;103(9):1173-1178; discussion 1178. doi: 10.1111/j.1464-410X.2008.08208.x.
12. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castrationresistant prostate cancer. Eur Urol. 2014;65(2):467-479. doi: 10.1016/j.eururo.2013.11.002.
13. Heijmink SW, Fütterer JJ, Hambrock T, Takahashi S, Scheenen TW, Huisman HJ, et al. Prostate cancer: bodyarray versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology. 2007;244(1):184-195.
14. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751–756.
15. Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediateterm potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology. 2007;69(6):1170-1175.
16. Van poppel LH, Joniau S, Haustermans K. Surgery alone for advanced prostate cancer? Eur J Cancer Suppl. 2007;157-169.
17. Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009;55(6):1251-1265. doi: 10.1016/j.eururo.2009.03.012.
18. Heidenreich A, Ohlmann CH. The role of anatomic extented pelvic lymphadenectomy in men undergoing radical prostatectomy for prostate cancer. EAU Update Ser. 2005;3:98–106.
19. van den Ouden D, Hop WC, Schröder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol. 1998;160(4):1392-1397.
20. Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L. Radical prostatectomycan provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol. 2000;38:372–379.
21. Gontero P, Marchioro G, Pisani R, Zaramella S, Sogni F, Kocjancic E, et al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol. 2007;51(4):922-929; discussion 929-30.
22. Xylinas E, Daché A, Rouprêt M. Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer? BJU Int. 2010;106(11):1596-1600. doi: 10.1111/j.1464-410X.2010.09630.x.
23. Yuh B, Artibani W, Heidenreich A, Kimm S, Menon M, Novara G, et al. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: A systematic review. Eur Urol. 2014;65(5):918-927. doi: 10.1016/j.eururo.2013.05.026.
24. Schutz FA, Oh WK. Neoadjuvant and adjuvant therapies in prostate cancer. Urol Clin North Am. 2010;37(1):97-104. doi: 10.1016/j.ucl.2009.11.012.
25. Lou DY, Fong L. Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor. Urol Oncol. 2014 Feb 1. pii: S1078-1439(13)00500- 0. doi: 10.1016/j.urolonc.2013.12.001.
26. Van Poppel H. Neoadjuvant hormone therapy and radical prostatectomy: The jury is still out. Eur Urol Suppl. 2001;39:10–14.
27. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572-578.
28. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA. 2006;296(19):2329-2335.
29. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: A matched cohort study. J Urol. 2008;179(5):1830-1807; discussion 1837. doi: 10.1016/j.juro.2008.01.022.
30. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472-479.
31. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: A proposal for a standardized definition. J Clin Oncol. 2006;24(24):3973-3978.
32. Keane T, Gillatt D, Lawton C, Payne H, Tombal B. Treatment options in prostate cancer once primary therapy fails. Eur Urol. 2007;3(Suppl):344-353.
33. Akakura K, Suzuki H, Ichikawa T, Fujimoto H, Maeda O, Usami M, et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: Results at median follow-up of 102 months. Jpn J Clin Oncol. 2006;36(12):789-793.
34. Saito T, Kitamura Y, Komatsubara S, Matsumoto Y, Sugita T, Hara N. Outcomes of locally advanced prostate cancer: A single institution study of 209 patients in Japan. Asian J Androl. 2006;8:555–556.
35. Johnstone PA, Ward KC, Goodman M, Assikis V, Petros JA. Radical prostatectomy for clinical T4 prostate cancer. Cancer. 2006;106(12):2603-2609.
36. Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011;60(2):205-210. doi: 10.1016/j.eururo.2011.03.011.
37. Rollig C, Wockel A, Weissbach L. Management of obstructive uropathy patients with advanced prostate cancer - a systematic review. Onkologie. 2009;32(11):680- 684. doi: 10.1159/000242250.
38. Crain DS, Amling CL, Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol. 2004;171:668–671.
39. Krupski TL, Stukenborg GJ, Moon K, Theodorescu D. The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU Int. 2010;106(10):1477-1483. doi: 10.1111/j.1464-410X.2010.09356.x.
40. Heung YM, Walsh K, Sriprasad S, Mulvin D, Sherwood RA. The detection of prostate cells by the reverse transcriptionpolymerase chain reaction in the circulation of patients undergoing transurethral resection of the prostate. BJU Int. 2000;85(1):65–69.